SYSTEMS, DEVICES, AND METHODS FOR TREATING METABOLIC MEDICAL CONDITIONS
Provided herein are systems for treating a patient, the systems comprising: a treatment device for treating a minimum amount of mucosal tissue of the patient's small intestine. The system is configured to treat a medical condition of the patient. Methods of treating a patient are also provided.
1 . (canceled)
2 . A method of treating a medical condition of a patient, the method comprising:
selecting a patient diagnosed with type 2 diabetes that is being treated with daily insulin;
performing a tissue treatment procedure comprising treating one or more segments of the selected patient's intestinal tissue; and
subsequent to performing the tissue treatment procedure, administering an agent comprising a GLP-1 receptor agonist to the patient;
wherein the method provides a therapeutic benefit to the patient.
3 . The method according to claim 2 , wherein the method further comprises the patient stopping the taking of insulin.
4 . The method according to claim 2 , wherein the therapeutic benefit comprises a reduction in the patient's daily insulin requirements.
5 . The method according to claim 2 , wherein the therapeutic benefit comprises an elimination of daily insulin requirements.
6 . The method according to claim 2 , wherein the therapeutic benefit comprises a reduction in the patient's HbA1c levels.
7 . The method according to claim 6 , wherein the patient's HbA1c levels are reduced by at least 0.7% three months after the tissue treatment procedure.
8 . The method according to claim 6 , wherein the patient's HbA1c levels are reduced by approximately 2.18% three months after the tissue treatment procedure.
9 . The method according to claim 2 , wherein the therapeutic benefit comprises a reduction in the patient's hepatic fat content.
10 . The method according to claim 9 , wherein the patient's hepatic fat content is reduced by at least 10%.
11 . The method according to claim 9 , wherein the patient's hepatic fat content is reduced by approximately 36%.
12 . The method according to claim 2 , wherein the intestinal tissue treated comprises duodenal tissue.
13 . The method according to claim 12 , wherein each segment of duodenal tissue treated comprises an axial length of at least 3 cm.
14 . The method according to claim 12 , wherein the duodenal tissue treated comprises a cumulative length axial length of at least 3 cm.
15 . The method according to claim 12 , wherein the duodenal tissue treated comprises a cumulative length axial length of at least 6 cm.
16 . The method according to claim 12 , wherein the duodenal tissue treated comprises a cumulative length axial length of at least 8 cm.
17 . The method according to claim 12 , wherein the duodenal tissue treated comprises a cumulative length axial length of at least 9 cm.
18 . The method according to claim 2 , wherein the tissue treatment procedure comprises ablation.
19 . The method according to claim 18 , wherein the tissue treatment procedure comprises ablation via hot fluid.
20 . The method according to claim 18 , wherein the tissue treatment procedure comprises ablation via an energy type selected from the group consisting of: electromagnetic; radiofrequency; light; laser light; sound; ultrasound; chemical; cryogenic; and combinations thereof.
21 . The method according to claim 2 , wherein the tissue treatment procedure further comprises a tissue expansion procedure.
22 . The method according to claim 21 , wherein the tissue expansion procedure comprises expansion of submucosal tissue proximate the one or more segments of the selected patient's intestinal tissue.
23 . The method according to claim 2 , wherein the agent is administered to the patient 14 days after the tissue treatment procedure.
24 . The method according to claim 2 , wherein the therapeutic benefit is present at least six months after the tissue treatment procedure.
25 . The method according to claim 2 , wherein the selected patient has not achieved good glycemic control with daily insulin.
26 . The method according to claim 25 , wherein good glycemic control comprises an HbA1c level less than 7.5%, such as less than 7%.
27 . The method according to claim 25 , wherein good glycemic control comprises an HbA1c level less than 7%.